Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19)

Molar Mass: 1498,37
C₆₃H₉₂IN₁₁O₂₃
[2192281-54-0] (net peptide)

Purity: > 95 %

Chemical Name: Sequence: Glu-CO-Lys[(Sub)DLys-DPhe-DTyr(3I)-DOTAGA] acetate

1. Schottelius M. et al. [111In] PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015, 5, 68.
2. Baum R.P. et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J. Nucl. Med. 2016, 57, 1006-1013.
3. Eiber M. et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J. Nucl. Med., 2016, 57(supplement 2): p. 61-61.